NVIDIA
NVDA
Tesla
TSLA
Super Micro Computer
SMCI
4
Palantir
PLTR
5
Applovin
APP
US Stock MarketDetailed Quotes
ITCI Intra-Cellular Therapies
- 128.460
- -0.120-0.09%
Close Feb 26 16:00 ET
- 129.680
- +1.220+0.95%
Pre 04:16 ET
13.66BMarket Cap-178.42P/E (TTM)
129.000High128.040Low1.60MVolume129.000Open128.580Pre Close205.13MTurnover1.53%Turnover RatioLossP/E (Static)106.33MShares129.00052wk High11.89P/B13.38BFloat Cap63.30052wk Low--Dividend TTM104.18MShs Float129.000Historical High--Div YieldTTM0.75%Amplitude6.750Historical Low128.391Avg Price1Lot Size
Intra-Cellular Therapies Key Stats
EPS
According to the latest financial report of Intra-Cellular Therapies, the latest earnings per share (TTM) for the company is -0.16. Investing in companies with strong earnings per share can potentially provide higher returns.
Currency: USD
Quarterly
Loading...
FCF
Interested in knowing about Intra-Cellular Therapies's free cash flow? The latest report shows it as -12.65M. Keep an eye on and closely monitor the company's cash flow to make informed investment decisions.
Currency: USD
Quarterly
Loading...
Current Ratio
If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of Intra-Cellular Therapies shows that the company's current ratio is 6.36, indicating healthy liquidity.
Currency: USD
Quarterly
Loading...
Quick Ratio
Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of Intra-Cellular Therapies, the quick ratio is 5.68, indicating that the company can meet its short-term debt obligations.
Currency: USD
Quarterly
Loading...
ROE
Want to learn more about the financial health of Intra-Cellular Therapies? The latest ROE figure is -1.47%, indicating that the company has stable profitability.
Currency: USD
Quarterly
Loading...
ROA
Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of Intra-Cellular Therapies, the total asset return on investment (ROA) is -1.25%.
Currency: USD
Quarterly
Loading...
Gross Margin
Gross margin can provide insight into a company's pricing strategy and cost structure. Check Intra-Cellular Therapies's latest financial report to see how their gross margin is doing - currently at 89.76%.
Currency: USD
Quarterly
Loading...
Net Margin
For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of Intra-Cellular Therapies, the net profit margin is -8.48%, which is a good sign for its profitability.
Currency: USD
Quarterly
Loading...